📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Inovio

1.1 - Company Overview

Inovio Logo

Inovio

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of DNA medicines and delivery technologies for HPV-associated diseases, cancer and infectious diseases. Offerings include VGX-3100, a DNA plasmid therapeutic vaccine designed to treat HPV-related high-grade anal lesions; CELLECTRA electroporation devices delivering DNA medicines without chemical adjuvants, lipid nanoparticles or viral vectors; DMAb DNA-encoded monoclonal antibodies (including dMAb-1/2); and INO-5401, an experimental vaccine aimed at preventing cancer in BRCA1/2 carriers (Phase 1).

Products and services

  • CELLECTRA Delivery Devices: Proprietary, electroporation-based instruments that deliver DNA medicines directly into cells, enabling uptake without chemical adjuvants, lipid nanoparticles, or viral vectors
  • DMAb (DNA-Encoded Monoclonal Antibodies): A DNA-encoded platform that produces monoclonal antibodies in vivo from delivered sequences, potentially treating infectious diseases and cancer via endogenous antibody generation
  • VGX-3100: A plasmid-based therapeutic vaccine engineered to treat HPV-related high-grade anal lesions, enhancing antigen-specific immune responses when administered with electroporation for cellular uptake

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Inovio

Zymeworks Logo

Zymeworks

HQ: Canada Website
  • Description: Provider of computational biotechnology for optimizing therapeutic antibodies and other protein-based therapeutics, with a pipeline of bispecific antibodies and antibody-drug conjugates targeting HER2, folate receptor-α, mesothelin, glypican-3, and NaPi2b, including zanidatamab, zanidatamab zovodotin, ZW191, ZW171, ZW251, and ZW220.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Zymeworks company profile →
Allarity Logo

Allarity

HQ: United States Website
  • Description: Provider of biopharmaceutical oncology therapies and predictive diagnostics for personalized cancer treatment, utilizing DRP Technology to predict patient response and refine patient selection. Pipeline includes Dovitinib for renal cell carcinoma, Stenoparib, LiPlaCis, and 2X-111.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Allarity company profile →
GeminX Pharmaceuticals Logo

GeminX Pharmaceuticals

HQ: Canada Website
  • Description: Provider of novel, targeted cancer therapeutics, dedicated to the discovery, development and commercialization of treatments based on research on the Bcl-2 cell death regulation pathway, including the discovery of GX15-070 (obatoclax), a novel small molecule.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full GeminX Pharmaceuticals company profile →
MediWise Logo

MediWise

HQ: United Kingdom Website
  • Description: Provider of medical research and development, pioneering cutting-edge wireless devices for medical diagnostics and monitoring.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full MediWise company profile →
Proteovant Therapeutics Logo

Proteovant Therapeutics

HQ: United States Website
  • Description: Provider of biotechnology solutions utilizing protein degradation research to develop medicines for diseases.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Proteovant Therapeutics company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Inovio

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Inovio

2.2 - Growth funds investing in similar companies to Inovio

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Inovio

4.2 - Public trading comparable groups for Inovio

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Inovio

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Inovio

What does Inovio do?

Inovio is a provider of DNA medicines and delivery technologies for HPV-associated diseases, cancer and infectious diseases. Offerings include VGX-3100, a DNA plasmid therapeutic vaccine designed to treat HPV-related high-grade anal lesions; CELLECTRA electroporation devices delivering DNA medicines without chemical adjuvants, lipid nanoparticles or viral vectors; DMAb DNA-encoded monoclonal antibodies (including dMAb-1/2); and INO-5401, an experimental vaccine aimed at preventing cancer in BRCA1/2 carriers (Phase 1).

Who are Inovio's competitors?

Inovio's competitors and similar companies include Zymeworks, Allarity, GeminX Pharmaceuticals, MediWise, and Proteovant Therapeutics.

Where is Inovio headquartered?

Inovio is headquartered in United States.

How many employees does Inovio have?

Inovio has 1,000 employees 🔒.

When was Inovio founded?

Inovio was founded in 2010 🔒.

What sector and industry vertical is Inovio in?

Inovio is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Inovio

Who are the top strategic acquirers in Inovio's sector and industry

Top strategic M&A buyers and acquirers in Inovio's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Inovio?

Top strategic M&A buyers groups and sectors for Inovio include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Inovio's sector and industry vertical

Which are the top PE firms investing in Inovio's sector and industry vertical?

Top PE firms investing in Inovio's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Inovio's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Inovio's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Inovio's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Inovio include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Inovio's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Inovio?

The key public trading comparables and valuation benchmarks for Inovio include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Inovio for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Inovio with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Inovio's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Inovio with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Inovio's' sector and industry vertical?

Access recent funding rounds and capital raises in Inovio's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Inovio